General Atlantic
SPTX icon

General Atlantic’s Seaport Therapeutics SPTX Stock Holding History

General Atlantic’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$123M Hold
6,101,582
– – 4.96% 6
2026
Q2 		$133M Buy
+6,101,582
New +$107M 4.56% 7

Other funds holding SPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $126B AUM 27.87% 1-Year Est. Return

General Atlantic's SPTX Position: Q3 2026 in Review

General Atlantic held its Seaport Therapeutics (SPTX) position steady in Q3 2026 at 6,101,582 shares worth $123M. The position accounts for 4.96% of the portfolio, ranked #6.

General Atlantic first reported a position in SPTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $133M in Q2 2026. 40 funds tracked by Wall St. Rank hold SPTX as of Q3 2026.

  • General Atlantic held 6,101,582 shares of Seaport Therapeutics worth $123M as of Q3 2026.
  • General Atlantic left its Seaport Therapeutics share count unchanged in Q3 2026.
  • Seaport Therapeutics made up 4.96% of General Atlantic's portfolio in Q3 2026, its #6 holding.
  • General Atlantic first reported a position in Seaport Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • General Atlantic's Seaport Therapeutics position peaked at $133M in Q2 2026.
  • 40 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q3 2026.

Based on General Atlantic's 13F filing for Q3 2026, filed 13 Nov 2026.